澳大利亚、美国和日本HPV疫苗接种项目的获益-风险评估
本研究采用伤残调整生命年(DALY)率对澳大利亚(2013-2020)、美国(2013-2020)和日本(2013-2024)每10万名合格女孩的HPV疫苗接种项目进行统一获益-风险评估。结果显示接种覆盖率分别为澳大利亚78.3%、美国50.1%、日本21.4%,期望净值分别为52.9、56.7和23.4。日本2021年恢复积极推荐后获益-风险比提高7.9倍,主要因不良事件报告减少。
要点
- 澳大利亚和美国HPV疫苗接种项目显示出强获益-风险特征。
- 日本期望净值较低主要归因于低接种覆盖率和高宫颈癌DALY率。
- 日本2021年恢复积极推荐后获益-风险比提高7.9倍。
核心结论
- 日本期望净值低于澳大利亚和美国,主要归因于低接种覆盖率和高宫颈癌DALY率。
- 澳大利亚和美国HPV疫苗接种项目显示出强获益-风险特征。
- 日本近期政策变化和教育举措减少了不良事件担忧,但需进一步努力提高覆盖率至国际基准。
研究设计与样本
- 使用DALY率进行统一获益-风险评估,量化每10万名合格女孩的HPV疫苗接种项目期望净值。
- 评估时段:澳大利亚2013-2020年,美国2013-2020年,日本2013-2024年。
- 数据来源:国家卫生机构和2019年全球疾病负担研究。
主要发现
- 接种覆盖率:澳大利亚78.3%,美国50.1%,日本21.4%。
- 期望净值:澳大利亚52.9,美国56.7,日本23.4。
- 各国不良事件报告率均<0.05%,多数报告涉及神经系统疾病和非特异性症状。
- 日本2021年恢复积极疫苗接种推荐后,获益-风险比提高7.9倍,主要因不良事件报告减少。
临床怎么用
- 实现与澳大利亚和美国相当的接种率可显著改善结局。
- 日本需进一步努力提升接种覆盖率至国际基准。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Human papillomavirus (HPV) vaccination is a global strategy for the prevention of cervical cancer (CC). Although Australia and the United States (US) have achieved high coverage, the cumulative HPV rate of the first vaccination for Japanese females born in 2008 was approximately 55%, despite policy efforts. This study compared the situation in Japan with that in Australia and the US, where vaccination rates are higher. METHODS: We conducted a unified benefit-risk assessment using disability-adjusted life year (DALY) rates to quantify the expected net value (ENV) of HPV vaccination programs per 100,000 eligible girls in Australia (2013-2020), the US (2013-2020), and Japan (2013-2024). Data on vaccination coverage, adverse events (AEs), and CC incidence were sourced from national health agencies and the Global Burden of Disease Study 2019. RESULTS: The vaccination coverage was 78.3% in Australia, 50.1% in the US, and 21.4% in Japan during the survey period. The ENV gained were 52.9 for Australia, 56.7 for the US, and 23.4 for Japan, reflecting differences in vaccination rates and CC burden. Across countries, the reporting rate of AEs was <0.05%, with most reports related to nervous system disorders and nonspecific symptoms. The benefit-to-risk ratio in Japan improved 7.9-fold after the resumption of active vaccination recommendations in 2021, largely owing to reduced reports of AEs. CONCLUSION: Japan's lower ENV gained compared to those of Australia and the US is primarily attributable to its low vaccination coverage and higher DALY rate for CC. HPV vaccination programs in Australia and the US have demonstrated strong benefit-risk profiles. Achieving vaccination rates comparable to those in Australia and the US can substantially improve outcomes. Japan's recent policy changes and educational initiatives have reduced AE concerns; however, further efforts are needed to raise the coverage of international benchmarks.
引用
- Satake M, Ito S, Sawano C, et al. Benefit-risk assessment of HPV vaccination programs in Australia, the United States, and Japan. Vaccine. 2026. PMID: 41785681. doi:10.1016/j.vaccine.2026.128407
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。